STING-IN-13
STING-IN-13 is a selective STING inhibitor. STING-IN-13 can effectively inhibit downstream signaling of the STING pathway and inhibit STING-mediated inflammation. STING-IN-13 has low toxicity and can be used to study STING-related inflammatory and autoimmune diseases.
For research use only. We do not sell to patients.
- Formula: C19H18F3N3O2
- Molecular Weight:377.36
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
In Vitro
STING-IN-13 (Compound HY2) (30 μM) shows direct interaction with STING in RAW264.7 cells[1].
STING-IN-13 (0.03 μM-0.3 μM, pre-treat for 1 h, then co-incubation for 2-4 h) effectively inhibits the downstream signaling of the STING pathway in THP1 and RAW264.7 cells induced by SR717 (HY-131454), and effectively reduces the production of inflammatory factors IFN-β and CXCL10[1].
STING-IN-13 (0.4 μM-3.3 μM, 48 h) has excellent safety and low cytotoxicity in THP1 cells[1].
STING-IN-13 (5 μM, pre-treat for 1 h, then treat for 2 h) specifically inhibits STING-driven IFNβ expression in THP1 cells without affecting the TLR pathway[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:SR717 (30 μM) treated THP1 and RAW264.7 cells
-
Concentration:0.03 μM-0.3 μM
-
Incubation Time:Pretreatment for 1 h, then SR717 treatment for 4 h
-
Result:Dose-dependently reduced IFN-β and CXCL10 levels induced by SR717 in THP1 and RAW264.7 cells.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 mice (male, aged 8 weeks) injected with Cisplatin (25 mg/kg)[1]
-
Dosage:10,20 mg/kg
-
Administration:i.p. one dose
-
Result:Effectively improved the survival rate (100% vs 33.3% in the Cisplatin group).
Reduced BUN and creatinine levels, protected renal function, and reduced AST and ALT levels, protecting the liver.
Reduced renal tubular damage and inflammatory cell infiltration.
Chemical Information
-
Molecular Weight 377.36
-
Formula C19H18F3N3O2
-
SMILES
O=C(NC1=CC=C(OCCCC(F)(F)F)C=C1)NC2=CNC3=CC=CC=C32
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
STING-IN-13 Related Classifications
HY-173317 Related Classifications
Powered by Bioz